Site icon Market Globalist

Why did Predictive Oncology Inc. (POAI) stock skyrocket on Tuesday?

TGT Stock

TGT Stock

Predictive Oncology Inc. (POAI) shares surged 24.74% in after-hours on Tuesday, September 21, 2021, and closed the daily trading at $1.21. in the regular trading session of Friday, POAI’s stock gained 1.04%. POAI shares have risen 13.45% over the last 12 months, and they have moved down 2.16% in the past week. Over the past three months, the stock has lost 5.83%, while over the past six months, it has declined 27.07%.

Let’s discuss its recent news and developments.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


>> 7 Top Picks for the Post-Pandemic Economy << 

POAI corporate update

On September 15, 2021, Predictive Oncology (POAI) announced that Raymond F. Vennare was elected to the Board of Directors.

Mr. Vennare has more than thirty years of experience as an accomplished senior executive, board director, and biotechnology entrepreneur to Predictive Oncology, Inc.

Read More

POAI annual special meeting results

On August 17, 2021, Predictive Oncology (POAI) stockholders approved an amendment to the Company’s certificate of incorporation to increase the number of authorized shares of Company common stock from 100,000,000 to 200,000,000, and the amendment became effective on August 17, 2021.

POAI latest financial results

On August 11, 2021, Predictive Oncology (POAI) reported financial results for the quarter that ended on June 30, 2021.

Q2 2021 financial highlights

 Conclusion

POAI exceptional performance on Tuesday has no grounds. We were unable to find any recent news or development which could be the reason behind its gains on Tuesday. Let’s see how it performs in the coming trading sessions.

>> 7 Top Picks for the Post-Pandemic Economy << 

About the company

Predictive Oncology Inc. (POAI) is a knowledge-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. The company operates through three segments (Skyline, Helomics, and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical, and Soluble Biotech. The company has

Exit mobile version